Skandinaviska Enskilda Banken AB publ Sells 3,494 Shares of Becton, Dickinson and Company $BDX

Skandinaviska Enskilda Banken AB publ decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 5.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,163 shares of the medical instruments supplier’s stock after selling 3,494 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Becton, Dickinson and Company were worth $11,261,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of BDX. Gilbert & Cook Inc. lifted its stake in shares of Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after purchasing an additional 56 shares during the last quarter. Mendel Money Management lifted its position in shares of Becton, Dickinson and Company by 2.6% during the second quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock valued at $388,000 after buying an additional 58 shares during the last quarter. Focus Financial Network Inc. boosted its holdings in shares of Becton, Dickinson and Company by 2.2% in the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after buying an additional 58 shares in the last quarter. Phillips Wealth Planners LLC grew its position in shares of Becton, Dickinson and Company by 2.7% in the 3rd quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock worth $430,000 after buying an additional 58 shares during the last quarter. Finally, CX Institutional raised its stake in shares of Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BDX. Citigroup cut their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Jefferies Financial Group reduced their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Piper Sandler reissued a “neutral” rating and issued a $170.00 price target (down previously from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Finally, Zacks Research downgraded shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $195.46.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,416 shares of company stock valued at $675,557 over the last 90 days. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Up 3.1%

Shares of BDX stock opened at $182.82 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $185.02. The firm has a market capitalization of $52.06 billion, a PE ratio of 29.82, a P/E/G ratio of 2.32 and a beta of 0.25. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The stock’s 50-day simple moving average is $198.01 and its 200-day simple moving average is $192.26.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the company posted $3.43 earnings per share. The company’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.